NCT01512667View on ClinicalTrials.gov

Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 17, 2012

Primary Completion Date

August 22, 2012

Study Completion Date

August 22, 2012

Conditions
Renal Insufficiency
Interventions
DRUG

MK-0822

A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01512667 - Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067) | Biotech Hunter | Biotech Hunter